Financials Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-06-12 EDT			5-day change	1st Jan Change
7.150 ^USD	+9.33%		+30.95%	-0.83%

05-23	Altimmune, Inc., Q1 2025 Earnings Call, May 13, 2025
05-19	Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder	RE

Projected Income Statement: Altimmune, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	8.185	4.41	-0.068	0.426	0.02	0.5586	25	20.71
Change	-	-46.12%	-101.54%	726.47%	-95.31%	2,692.8%	4,376.3%	-17.17%
EBITDA ¹	-	-96.36	-87.94	-95.45	-102.9	-106.9	-151.9	-188.4
Change	-	-	8.74%	-8.54%	-7.84%	-3.81%	-42.15%	-24.04%
EBIT ¹	-54.8	-85.54	-87.74	-83.51	-103.2	-112.7	-122.9	-172.8
Change	-	-56.11%	-2.57%	4.82%	-23.54%	-9.28%	-9.02%	-40.62%
Interest Paid ¹	-	-0.00566	-0.008	-0.035	-0.009	-0.5673	-0.001	-0.001
Earnings before Tax (EBT) ¹	-54.46	-97.09	-84.91	-88.45	-95.06	-107.7	-146.5	-154.9
Change	-	-78.27%	12.55%	-4.17%	-7.48%	-13.29%	-36.03%	-5.76%
Net income ¹	-49.04	-97.09	-84.71	-88.45	-95.06	-103.6	-138.4	-151.1
Change	-	-97.96%	12.75%	-4.41%	-7.48%	-8.97%	-33.62%	-9.17%
Announcement Date	2/25/21	3/15/22	2/28/23	3/27/24	2/27/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4
Net sales ¹	0.7216	2.938	2.313	0.8375	0.1376	0.1576	3.278	0.032	0.008	0.002	-0.11	0.021	0.006	0.362	0.037	0.005	0.005	0.005	0.005	0.005	-	-	-	-	-	-	-
Change	-	307.13%	-21.28%	-63.79%	-83.57%	14.49%	1,980.26%	-99.02%	-75%	-75%	-5,600%	119.09%	-71.43%	5,933.33%	-89.78%	-86.49%	0%	0%	0%	0%	-	-	-	-	-	-	-
EBITDA ¹	-18.35	-	-	-	-16.72	-32.92	-23.87	-19.38	-20.34	-24.89	-23.27	-21.4	-17.5	-21.99	-31.73	-26.69	-26.68	-24.73	-24.83	-21.79	-27.47	-27.74	-27.98	-	-30	-30.5	-
Change	-	-	-	-	-	-96.91%	27.5%	18.8%	-4.96%	-22.37%	6.53%	8.02%	18.23%	-25.63%	-44.32%	15.9%	0.01%	7.32%	-0.42%	12.27%	-26.08%	-0.99%	-0.85%	-	-	-1.67%	-
EBIT ¹	-18.42	-18.32	-10.75	-14.86	-16.79	-33.2	-20.68	-19.5	-20.4	-24.75	-23.09	-21.76	-18.01	-22.54	-21.2	-26.79	-26.74	-24.77	-24.87	-21.82	-27.19	-30.12	-33.63	-37.81	-35.03	-35.94	-41.86
Change	-	0.51%	41.34%	-38.25%	-13%	-97.72%	37.7%	5.73%	-4.6%	-21.36%	6.7%	5.78%	17.24%	-25.17%	5.93%	-26.36%	0.18%	7.4%	-0.4%	12.27%	-24.63%	-10.8%	-11.62%	-12.45%	7.35%	-2.6%	-16.46%
Charge d'intérêts ¹	-	-	-	-	-	-	-	-	-0.065	-0.064	0.183	-0.002	-0.002	-	-	-	-	-	-	-	-0.4	-0.4	-1	-	-	-	-
Earnings before Tax (EBT) ¹	-18.35	-18.25	-10.73	-14.86	-24.83	-33.51	-23.89	-19.43	-20.11	-23.71	-21.66	-20.07	-16.06	-20.67	-31.64	-24.39	-24.64	-22.84	-23.18	-20.26	-25.92	-28.96	-32.55	-36.39	-34.33	-35.26	-40.52
Change	-	0.51%	41.2%	-38.5%	-67.02%	-34.98%	28.71%	18.67%	-3.48%	-17.93%	8.66%	7.32%	19.99%	-28.7%	-53.07%	22.9%	-1.01%	7.28%	-1.47%	12.61%	-27.95%	-11.73%	-12.4%	-11.79%	5.64%	-2.69%	-14.92%
Net income ¹	-16.77	-17.77	-10.62	-14.86	-24.83	-33.51	-23.89	-19.43	-20.11	-23.52	-21.66	-20.07	-16.06	-20.67	-31.64	-24.39	-24.64	-22.84	-23.18	-19.58	-25	-28.02	-31.68	-36.39	-34.33	-35.26	-40.52
Change	-	-5.98%	40.23%	-39.94%	-67.02%	-34.98%	28.71%	18.67%	-3.48%	-16.95%	7.89%	7.32%	19.99%	-28.7%	-53.07%	22.9%	-1.01%	7.28%	-1.47%	15.55%	-27.71%	-12.08%	-13.08%	-14.84%	5.64%	-2.69%	-14.92%
Announcement Date	8/11/20	11/9/20	2/25/21	5/17/21	8/10/21	11/9/21	3/15/22	5/12/22	8/11/22	11/10/22	2/28/23	5/11/23	8/10/23	11/7/23	3/27/24	5/9/24	8/8/24	11/12/24	2/27/25	5/13/25	-	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Altimmune, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt ¹	-	-	-111	-135	-132	-131	-340	-429
Change	-	-	-	-21.62%	2.22%	0.71%	-159.54%	-26.18%
Announcement Date	2/25/21	3/15/22	2/28/23	3/27/24	2/27/25	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Altimmune, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
CAPEX ¹	0.204	12.12	0.126	0.047	-	0.6118	1.715	2.218
Change	-	5,840.92%	-98.96%	-62.7%	-	-	180.28%	29.32%
Free Cash Flow (FCF) ¹	-34.64	-90.36	-62.71	-75.86	-79.85	-83.2	-112.8	-159.7
Change	-	-160.84%	30.59%	-20.96%	-5.26%	-4.2%	-35.58%	-41.58%
Announcement Date	2/25/21	3/15/22	2/28/23	3/27/24	2/27/25	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Altimmune, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-	-2,184.92%	129,330.88%	-22,406.57%	-514,670%	-19,130.09%	-607.5%	-909.75%
EBIT Margin (%)	-669.5%	-1,939.62%	129,029.41%	-19,603.29%	-515,860%	-20,184.74%	-491.59%	-834.58%
EBT Margin (%)	-665.38%	-2,201.43%	124,867.65%	-20,762.21%	-475,295%	-19,279.7%	-585.9%	-748.09%
Net margin (%)	-599.2%	-2,201.43%	124,577.94%	-20,762.21%	-475,295%	-18,544.32%	-553.58%	-729.64%
FCF margin (%)	-423.22%	-2,048.7%	92,223.53%	-17,806.81%	-399,240%	-14,895.45%	-451.15%	-771.12%
FCF / Net Income (%)	70.63%	93.06%	74.03%	85.77%	84%	80.32%	81.5%	105.69%
Profitability
ROA	-	-	-	-	-	-	-	-
ROE	-	-	-	-	-59.84%	-106.25%	-118.08%	-93.58%
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	2.49%	274.74%	-185.29%	11.03%	-	109.54%	6.86%	10.71%
CAPEX / EBITDA (%)	-	-12.57%	-0.14%	-0.05%	-	-0.57%	-1.13%	-1.18%
CAPEX / FCF (%)	-0.59%	-13.41%	-0.2%	-0.06%	-	-0.74%	-1.52%	-1.39%
Items per share
Cash flow per share ¹	-	-	-	-	-1.125	-0.89	-1.02	-0.75
Change	-	-	-	-	-	20.86%	-14.61%	26.47%
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	-	-	-	1.707	0.9976	1.871	2.307
Change	-	-	-	-	-	-41.56%	87.58%	23.3%
EPS ¹	-1.91	-2.35	-1.81	-1.66	-1.34	-1.262	-1.533	-1.351
Change	-	-23.04%	22.98%	8.29%	19.28%	5.79%	-21.41%	11.85%
Nbr of stocks (in thousands)	36,968	39,644	49,146	53,729	71,125	81,107	81,107	81,107
Announcement Date	2/25/21	3/15/22	2/28/23	3/27/24	2/27/25	-	-	-